Express News | Lumos Pharma Announces Abstracts Reviewing Data From Its Phase 2 OraGrowth210 And OraGrowth212 Trials Will Be Presented At Upcoming Medical Meetings
Moomoo 24/7Apr 18 16:08 ET
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
Lumos Pharma, Inc. (NASDAQ:LUMO) announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.
GlobeNewswireApr 18 16:05 ET
Lumos Pharma's LUM-201 Receives 'Buy' Rating on Strong Market Position and Promising Trial Outcomes
TipRanksMar 20 11:45 ET
Express News | Lumos Pharma Announces USPTO Has Granted Patent Protection For Novel Formulation Of LUM-201, Extending Exclusivity To 2042
Moomoo 24/7Mar 20 08:06 ET
Lumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Yahoo FinanceMar 10 08:31 ET
Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 8 14:06 ET
Earnings Call: Lumos Pharma Reports Positive Trial Results for LUM-201
InvestingMar 8 07:50 ET
Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT)
TipRanksMar 8 06:30 ET
Earnings Call Summary | Lumos Pharma(LUMO.US) Q4 2023 Earnings Conference
The following is a summary of the Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript:Financial Performance:Lumos Pharma ended 2023 with $36.1 million in cash, cash equivalents, and short-term
moomoo AIMar 7 18:51 ET · Conference Call
Lumos Pharma: Q4 Earnings Insights
Lumos Pharma (NASDAQ:LUMO) reported its Q4 earnings results on Thursday, March 7, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsLumos Pharma missed estimated earni
BenzingaMar 7 16:10 ET
Express News | Lumos Pharma Q4 2023 GAAP EPS $(1.170) Misses $(1.150) Estimate, Sales $826.000K Beat $1.750K Estimate
Moomoo 24/7Mar 7 16:09 ET
Lumos Pharma 2023 Loss/Shr $4.18 >LUMO
Lumos Pharma 2023 Loss/Shr $4.18 >LUMO
Dow JonesMar 7 16:07 ET
Lumos Pharma: Cash on Hand as of Dec 31 Expected to Support Ops Through 3Q
Lumos Pharma: Cash on Hand as of Dec 31 Expected to Support Ops Through 3Q
Dow JonesMar 7 16:06 ET
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. • Stevanato Gr (NYSE:STVN) is likely to report quarte
BenzingaMar 7 04:49 ET
Notable Earnings After Thursday's Close
Seeking AlphaMar 6 17:35 ET
Earnings Preview: Lumos Pharma
Lumos Pharma (NASDAQ:LUMO) is set to give its latest quarterly earnings report on Thursday, 2024-03-07. Here's what investors need to know before the announcement.Analysts estimate that Lumos Pharma w
BenzingaMar 6 13:01 ET
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)
GlobeNewswireFeb 26 09:00 ET
Lumos Pharma(LUMO.US) Officer Sells US$1,328.02 in Common Stocks
$Lumos Pharma(LUMO.US)$ Officer McKew John C. sold 438 shares of Common Stocks on Feb 6, 2024 at an average price of $3.032 for a total value of $1,328.02.Source: Announcement What is statement of cha
moomoo NewsFeb 7 18:05 ET
Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced
GlobeNewswireFeb 5 16:05 ET
Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth?
Yahoo FinanceFeb 5 12:24 ET
No Data
No Data